1. Home
  2. CNTN vs HUMA Comparison

CNTN vs HUMA Comparison

Compare CNTN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canton Strategic Holdings Inc. Common Stock

CNTN

Canton Strategic Holdings Inc. Common Stock

SELL

Current Price

$2.04

Market Cap

178.5M

Sector

Health Care

ML Signal

SELL

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.37

Market Cap

165.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
HUMA
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.5M
165.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CNTN
HUMA
Price
$2.04
$0.37
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.63
AVG Volume (30 Days)
810.6K
★ 4.4M
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 88.10
79.37
EPS
★ N/A
N/A
Revenue
N/A
★ $2,038,000.00
Revenue This Year
N/A
$72.32
Revenue Next Year
N/A
$518.79
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$0.39
52 Week High
$5.27
$1.90

Technical Indicators

Market Signals
Indicator
CNTN
HUMA
Relative Strength Index (RSI) 41.64 19.61
Support Level $2.04 N/A
Resistance Level $2.40 $0.75
Average True Range (ATR) 0.16 0.03
MACD -0.04 -0.01
Stochastic Oscillator 5.06 3.53

Price Performance

Historical Comparison
CNTN
HUMA

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: